Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18469495 | 0.74 | PGR (0.33) | HTR2CHTR2B | |
| SCHEMBL3323535 | 0.71 | TRPV1 (0.43) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL3323531 | 0.71 | TRPV1 (0.43) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL3321846 | 0.68 | KDM1A (0.37) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL3322042 | 0.68 | TRPM8 (0.40) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL3320421 | 0.68 | TRPM8 (0.40) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL3323466 | 0.68 | KDM1A (0.37) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL3324005 | 0.68 | KDM1A (0.37) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL3323061 | 0.68 | TRPV1 (0.40) | KDM1ARCOR1TRPV1HTR2CHTR2B | |
| SCHEMBL17112284 | 0.68 | TRPV1 (0.43) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | KDM1A 1196/4885RCOR1 3980/4885TERT 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.